Ask AI
ProCE Banner Activity

Emerging TROP-2 and TIGIT Therapies in Lung Cancer

Slideset

Download these slides for the latest data for anti–TROP-2 ADCs and anti-TIGIT agents in NSCLC and SCLC.

Released: January 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate recently presented clinical research findings and expert guidance to support treatment selection and sequencing of investigational agents targeting TROP-2 and TIGIT in patients with lung cancer

  • Identify appropriate patients for enrollment in clinical trials of TROP-2–directed ADCs and anti-TIGIT/anti–PD-L1 combinations in lung cancer